Key result
Several therapeutic compounds, including fluoxetine and probucol, induce acquired long QT syndrome by inhibiting hERG channel trafficking rather than direct channel block.
Highlights a novel mechanism of drug-induced long QT syndrome via inhibition of hERG channel trafficking, which may evade standard safety screening.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to possible false-negative hERG screening; leaves open whether trafficking assays should supplement current safety protocols.
The cardiac potassium channel hERG (human ether-a-go-go-related gene) encodes the alpha-subunit of the rapid delayed rectifier current I(Kr) in the heart, which contributes to terminal repolarization in human cardiomyocytes. Direct block of hERG/I(Kr) channels by a large number of therapeutic compounds produces acLQTS [acquired LQTS (long QT syndrome)] characterized by drug-induced QT prolongation and torsades de pointes arrhythmias. The cardiotoxicity associated with unintended hERG block has prompted pharmaceutical companies to screen developmental compounds for hERG blockade and made hERG a major target in drug safety programmes. More recently, a novel form of acLQTS has been discovered that may go undetected in most conventional safety assays. Several therapeutic compounds have been identified that reduce hERG/I(Kr) currents not by direct block but by inhibition of hERG/I(Kr) trafficking to the cell surface. Important examples are antineoplastic Hsp90 (heat-shock protein 90) inhibitors such as (i) geldanamycin, (ii) the leukaemia drug arsenic trioxide, (iii) the antiprotozoical pentamidine, (iv) probucol, a cholesterol-lowering drug, and (v) fluoxetine, a widely used antidepressant. Increased awareness of drug-induced hERG trafficking defects will help to further reduce the potentially lethal adverse cardiac events associated with acLQTS.
No takes yet. Share an insight, caveat, or question.
Dennis et al. (2007) conducted a review in acquired long QT syndrome (acLQTS). hERG channel trafficking inhibitors was evaluated. Several therapeutic compounds, including fluoxetine and probucol, induce acquired long QT syndrome by inhibiting hERG channel trafficking rather than direct channel block.
Synapse has enriched 10 related papers. Consider them for comparative context: